Mounjaro for PCOS weight loss: what the evidence shows and what to ask your prescriber

Why losing weight with PCOS is a different physiological problem

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity and no diabetes over 72 weeks. Participants on the highest dose saw an average body-weight reduction of around 20 to 21 per cent, a figure that received wide clinical attention because it substantially exceeds what previous single-pathway medicines produced. What is relevant to PCOS specifically is not just the scale of that reduction, but the mechanism behind it.

Tirzepatide is the only dual GIP and GLP-1 receptor agonist licensed for weight management in the UK. GIP and GLP-1 are gut hormones involved in both appetite regulation and glucose metabolism. Many women with PCOS have a degree of insulin resistance, their cells respond less efficiently to insulin, which in turn drives higher circulating insulin levels, promotes fat storage (particularly around the abdomen), and can blunt the hormonal feedback loops that tell the brain to stop eating. Addressing insulin signalling is therefore not incidental to PCOS weight management; it is central to it. You can read more about the licensed uses on our Mounjaro overview page.

That said, SURMOUNT-1 did not specifically recruit a PCOS cohort, and no large randomised controlled trial has yet tested tirzepatide as a PCOS treatment in its own right. The connection between the mechanism and the condition is clinically plausible and increasingly discussed, but it remains an area where the evidence is still building.

What is actually known about Mounjaro and PCOS outcomes

The honest position, supported by NICE's appraisal of tirzepatide (TA1026), is that tirzepatide is recommended for weight management, not for PCOS as a named indication. The NICE recommendation covers adults with a BMI of 35 or above alongside at least one weight-related comorbidity, within the NHS pathway; private prescribing follows the licensed SmPC, which sets thresholds at BMI 30 or above, or 27 or above with a qualifying condition.

Where PCOS intersects with those thresholds, there is genuine clinical interest in whether weight reduction via tirzepatide also improves PCOS-related outcomes (including menstrual regularity, androgen levels and fertility) because these often track with weight and insulin sensitivity. Smaller observational studies and case series have reported improvements in cycle regularity alongside meaningful weight loss in women with PCOS taking GLP-1-type medicines. A prescriber familiar with your full picture, including any endocrinology input you already have, is the right person to assess whether those potential benefits apply to you.

Our page on whether Mounjaro is a good fit for PCOS goes into more detail on the specific outcomes reported in the literature, and our page on Mounjaro and PCOS together covers the broader picture of the two conditions.

Contraception, conception and pregnancy: the facts for women with PCOS

This is where caution matters most. Tirzepatide is not recommended during pregnancy, during breastfeeding, or if you are actively trying to conceive. That guidance is clear. For women with PCOS, there is an additional layer worth knowing: because PCOS can disrupt menstrual cycles, some women assume their fertility is low, but meaningful weight loss can restore ovulation unpredictably. Starting Mounjaro and losing weight may increase your fertility before you expect it to.

The MHRA advises using contraception while on tirzepatide and for a wash-out period before trying to conceive. If you use oral contraceptives, you should add a non-oral method (condoms, for example) for the first four weeks of treatment and for four weeks after each dose increase, because the slowed gastric emptying associated with tirzepatide may reduce pill absorption. This is covered in the NHS England guidance on weight-management injections, and it is a conversation worth having with a prescriber before you start rather than after.

If you are planning a pregnancy in the near future, the timing of any treatment and the contraception plan around it should be part of your consultation. Our page on taking Mounjaro with PCOS addresses eligibility and these practical considerations together.

Starting a conversation with a prescriber: what to bring and what to expect

A question our prescribers hear regularly is whether PCOS alone qualifies someone for Mounjaro. The BMI thresholds in the licence are the clinical floor, not a guarantee, your prescriber weighs your full health picture, including any existing conditions, current medications, and whether you are using hormonal contraception. If you have a diagnosis of PCOS, that is relevant context. If you are also being managed by a gynaecologist or endocrinologist, letting your prescriber know means they can consider your care as a whole.

Mounjaro's licensed use alongside diet and activity is covered on the Mounjaro for diabetes or weight loss page, which may be useful background. Cost is a practical concern for many people considering private treatment; the UK price context page explains what happened to Mounjaro pricing in late 2025 and what to expect now.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, not a form processed by software. If you are ready to have that conversation, you can do so before the 12pm cut-off Monday to Friday and, if approved, your treatment dispatches the same day. Speak to our prescribers via the free consultation to discuss whether Mounjaro is clinically appropriate for your situation.